Zacks Research Has Bullish Estimate for BHC Q2 Earnings

Bausch Health Companies Inc. (NYSE:BHC) – Investment analysts at Zacks Research boosted their Q2 2025 EPS estimates for Bausch Health Companies in a report issued on Tuesday, March 11th. Zacks Research analyst R. Department now expects that the company will earn $1.05 per share for the quarter, up from their prior forecast of $1.04. The consensus estimate for Bausch Health Companies’ current full-year earnings is $4.41 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2026 earnings at $1.24 EPS, FY2026 earnings at $4.72 EPS and FY2027 earnings at $5.67 EPS.

Several other research analysts have also commented on BHC. Royal Bank of Canada cut their price objective on Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating for the company in a report on Thursday, January 30th. Jefferies Financial Group restated a “hold” rating and set a $8.00 target price (down previously from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $7.42.

Bausch Health Companies Price Performance

BHC opened at $6.79 on Thursday. The company has a market capitalization of $2.50 billion, a price-to-earnings ratio of -56.54, a P/E/G ratio of 0.37 and a beta of 0.59. Bausch Health Companies has a 1 year low of $3.96 and a 1 year high of $11.46. The firm’s fifty day moving average price is $7.27 and its two-hundred day moving average price is $7.65.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.44). Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. The firm had revenue of $2.56 billion for the quarter, compared to the consensus estimate of $2.51 billion.

Institutional Investors Weigh In On Bausch Health Companies

Institutional investors have recently made changes to their positions in the company. Mountain Hill Investment Partners Corp. bought a new stake in shares of Bausch Health Companies in the 4th quarter valued at about $56,000. Bank of Nova Scotia acquired a new stake in Bausch Health Companies during the 4th quarter valued at approximately $83,000. One68 Global Capital LLC acquired a new stake in Bausch Health Companies during the 4th quarter valued at approximately $90,000. Balyasny Asset Management L.P. acquired a new stake in Bausch Health Companies during the 4th quarter valued at approximately $97,000. Finally, Alpine Global Management LLC acquired a new position in shares of Bausch Health Companies in the 4th quarter valued at $114,000. Institutional investors own 78.65% of the company’s stock.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.